Google the subject of this post. The article is not a cheery one but the message is clear. The need for these kinds of drugs is going to continue to explode. CBST is the leader in this field. Of course they`re not even mentioned in the article.. cause the crooks on wall street want shares on sale. Same reason Cantor Fitzgerald downgraded cbst yesterday. What a circus. Doesn't mean us little guys can't accumulate too though!
from a purely machiavellian and long-term view... these incentives make sense. With a totalitarian state it could happen. In the west I don't see it playing out though. The west needs to get healthcare costs under control. superbugs are a drain on the health care system. Prevention is key, such as proper sterilization procedures at hospitals. But prevention also means agressively treating existing cases so there is less time for contagion. Want to see clear evidence the government is taking this threat seriously? drum roll please.... The FDA's recent QIDP grant for ceftolozane/tazobactam in HABP/VABP and cUTI, as well as FDA's Fast track status provided for ceftolozane/tazobactam (CXA-201) in cIAI and for surotomycin (CB-315) in CDAD.